New Covid-19 Vaccine is released

Johnson & Johnson has submitted its single-dose COVID-19 vaccine candidate for an emergency use authorization from the Food and Drug Administration. “Today’s submission for Emergency Use Authorization of our investigational single-shot COVID-19 vaccine is a pivotal step toward reducing the burden of disease for people globally and putting an end to the pandemic,” Johnson & Johnson chief scientific officer and vice chairman Paul Stoffels, M.D., said in a statement Thursday. “Upon authorization of our investigational COVID-19 vaccine for emergency use, we are ready to begin shipping. With our submission to the FDA and our ongoing reviews with other health authorities around the world, we are working with great urgency to make our investigational vaccine available to the public as quickly as possible.”

The vaccination made by Johnson and Johnson, it would be the third vaccine available for emergency use, the other two are vaccines from Pfizer and BioNTech and Moderna. 

If authorized, the vaccine is estimated to be able to remain stable for two years at -4 degrees Fahrenheit, or -20 degrees Celsius. The vaccine can also be stored in the majority of standard refrigerators at temperatures of 36 to 46 degrees Fahrenheit for at least three months.

The announcement comes after Johnson & Johnson released data from the vaccine candidate’s Phase 3 clinical trial which showed the vaccine being 66 percent effective against moderate to severe COVID-19 cases 28 days after vaccination. However, the efficacy of the vaccine varies from country to country. The level of protection against moderate to severe COVID-19 infection was 72 percent in the United States, 66 percent in Latin America and 57 percent in South Africa, where there is a new strain.

Janssen, the company’s pharmaceutical subsidiary, intends to distribute vaccine doses to the Federal Government as soon as the FDA approves, and they expect to supply 100 million doses in the United States before July of 2021. The Department of Health and Human Services announced in August that it had reached an agreement with  Janssen to purchase 100 million doses for $1 billion. The agreement gives the government the option to purchase an additional 200 million doses.

The U.S. Centers for Disease Control and Prevention had reported on Thursday that over 35.2 million vaccine doses have been administered. According to Johns Hopkins University, the coronavirus has infected 26.6 million Americans and has killed more than 455,000 Americans since the pandemic began.